Hywel Dda sets July 2027 deadline for costed cancer plan

Hywel Dda University Health Board has agreed to produce a costed cancer improvement plan by July 2027 after Audit Wales found that services lacked a single long-term strategy linking priorities to resources. The audit, published on 19 October, says the board has managed rising demand but relies on fragmented plans and improvement work that is not consistently tracked or evaluated.

Demand has grown

The report records a 24% rise in new suspected-cancer referrals between 2022-23 and 2025-26. It recognises work to redesign pathways, expand diagnostic capacity and strengthen staffing, while finding that many responses address immediate pressures. Auditors say cancer waiting-time performance remains below the national standard used in the report: 75% of patients starting their first treatment within 62 days of cancer being suspected. The review describes earlier reporting periods, rather than current October performance.

What the board has agreed

The published management response accepts all six recommendations. The chief operating officer is responsible for the strategic improvement plan, which is due by July 2027 and is intended to align with the forthcoming national cancer strategy. The board says a cancer improvement workstream will begin in November 2026 to track actions, with stronger arrangements for consistent reporting. It gives December 2027 as the completion date for more detailed cancer pathway and performance reports to the Finance and Performance Committee. Those dates are the board’s planned milestones. The response does not establish that the promised changes have already been delivered.

Oversight and the limits of the review

Audit Wales found clear operational leadership and escalation routes, but says inconsistent reporting and limited use of outcomes data weaken longer-term scrutiny. It wants the board to make better use of information about diagnosis, mortality and patient experience when planning services. The audit did not assess clinical quality, clinical governance or patient experience, and did not audit the underlying data. Its findings concern how services are organised, monitored and improved, rather than the care received by any identified patient.